Industry News
Pharmaceutical Industry News

Glaukos is teaming up with…
Glaukos is teaming up with four-time NBA champion, two-time NBA Most Valuable Player and Olympic gold medalist Stephen Curry for a new “Could it be KC?” campaign.
Otsuka ICU Medical, a joint…
Otsuka ICU Medical, a joint venture from Japan’s Otsuka Pharmaceutical Factory, issued a voluntary recall of one lot of 0.9% sodium chloride injection for IV due to a possible mix-up of labels.
Have GLP-1 Drugs Changed How You Travel? Tell Us About It.
The New York Times wants to know how a GLP-1 medication may have affected how readers plan vacations.
Biogen has teamed with gymnast…
Biogen has teamed with gymnast Suni Lee for a campaign, leveraging the Olympic gold medalist’s health journey and social media audience to vault deeper into kidney health awareness.
The Ozempic and Wegovy maker’s CEO…
The Ozempic and Wegovy maker's CEO said he's open to a direct listing of Novo's shares on the New York Stock Exchange, but no such transition is currently underway.
Sign-ups for Medicare’s GLP-1…
Sign-ups for Medicare’s GLP-1 coverage plan keep expanding, and Eli Lilly is dominating the market with 70% share, the company’s CEO David Ricks said.
Despite hitting a speed bump over…
Despite hitting a speed bump over the summer, automated cell therapy manufacturing specialist Cellares has continued to sign new partners at a steady pace, now inking a second agreement with an Asia-based organization in just
AstraZeneca has re-upped its…
AstraZeneca has re-upped its UNICEF-partnered Young Health Programme, committing to a new five-year phase that will move total investment in the initiative above $100 million.
Hayden Panettiere’s Death Caused by Overdose of Fentanyl and Other Drugs
Ms. Panettiere, who starred in “Heroes” and “Nashville,” died last month at the age of 36. Her death was ruled accidental.
Genentech’s chief marketing…
Genentech's chief marketing officer Zoë Lazarre, Ph.D., likens AI to a “armor, or a digital backpack” that her teams can use for better, faster insights, she said during an interview at Fierce Pharma Week.
Bristol Myers Squibb plans to lay…
Bristol Myers Squibb plans to lay off another 265 employees tied to its corporate headquarters in New Jersey, bringing the number of total job reductions the company has announced this year in the Garden State
As China and the U.S. presently…
As China and the U.S. presently duke it out over biopharma innovation supremacy, a clutch of Europe’s biggest drugmakers are calling on the bloc to not lose sight of its R&D roots.
Eric Dube, Ph.D., the CEO who…
Eric Dube, Ph.D., the CEO who rebranded Travere Therapeutics and oversaw the launch of its rare kidney disease drug Filspari, will step down to “focus on his health and family.” Bradley Campbell, formerly CEO of
Book Review: ‘The Age of Cures,’ by Barry Werth
In “The Age of Cures,” the journalist Barry Werth shows how American drug manufacturers got big and then came under attack.
Par Health issued a voluntary…
Par Health issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection that may be contaminated with cellulose or stopper material.
One in three women in the U.K….
One in three women in the U.K. feel their migraine pain “is taken less seriously by others because of their gender.”
The president announced plans to…
The president announced plans to split some childhood immunizations in the U.S. into five separate shots, given as “20% doses” every six months. The decision has garnered significant backlash from the medical community.
As Johnson & Johnson’s $14.6…
As Johnson & Johnson’s $14.6 billion bet on Intra-Cellular Therapies continues to pay off with blockbuster sales of Caplyta, the atypical antipsychotic has passed a phase 3 test that puts it one step closer to
Amid lawmaker and advocacy group…
Amid lawmaker and advocacy group efforts to parse the White House’s “most favored nation” drug pricing deals with drugmakers, newly revealed—yet heavily redacted—information is reigniting concerns about just who exactly the Trump administration policy benefits.
IntraBio’s streak of success in…
IntraBio's streak of success in the rare neurological category continues, as the drugmaker racks up a second indication for Aqneursa, now the first treatment in the world indicated for a rare ataxia.


